OTC · CVSI
Healthcare · Drug Manufacturers - Specialty & Generic
$0.02
Up+$0.00 (+2.56%)
Updated Aug 23, 2026, 5:37 AM
SID Score
4.2/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 0 trading sessions · Daily adjusted prices
CVSI does not have enough price history for the selected period.
Data unavailable
The requested market data was not found.
The latest Smart Investors Daily articles mentioning CVSI.
CVSI research
Company profile and research snapshot.
CV SCIENCES INC
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Dec 10, 2021 | Cantor Fitzgerald | Neutral | — |
| Mar 19, 2021 | Roth Capital | Neutral | — |
| Mar 19, 2021 | Piper Sandler | Neutral | — |
| Jan 29, 2021 | Cantor Fitzgerald | Neutral | — |
| Jun 12, 2020 | Cowen & Co. | Market Perform | — |
No generated briefing is available yet.
GlobeNewswire Inc. · Dec 6, 2025
The CBD nutraceuticals market is projected to grow from $9.75 billion in 2023 to $39.06 billion by 2032, driven by increasing consumer interest in natural wellness solutions and gradual product legalization.
Yahoo · Nov 14, 2025
Despite revenue declines, CV Sciences Inc (CVSI) focuses on product diversification and cost efficiency to drive future growth.
Yahoo · Nov 13, 2025
SAN DIEGO, CA / ACCESS Newswire / November 13, 2025 / CV Sciences, Inc. (OTCQB:CVSI) (the "Company", "CV Sciences", "our", "us" or "we"), a preeminent consumer wellness company specializing in hemp extracts and other proven science-backed, natural ...
SeekingAlpha · Nov 13, 2025
CV Sciences, Inc. (OTCQB:CVSI) Q3 2025 Earnings Call November 13, 2025 4:30 PM ESTCompany ParticipantsBrendan HawkinsJoseph Dowling - CEO, Secretary &...
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning CVSI.
No results
No recent SID articles mention CVSI.
